TITLE

FDA Actions

PUB. DATE
November 2009
SOURCE
Travel Medicine Advisor;Nov2009 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that U.S. Food and Drug Administration (FDA) has approved asenapine and has lowered the age limit for levocetirizine. It notes that asenapine has been approved by FDA as a first-line treatment for schizophrenia and bipolar I disorder in adults. Meanwhile, the age limit for intake of levocetirizine has been lowered to 6 months for children with chronic hives and perennial allergic rhinitis and 2 years for children with seasonal allergic rhinitis.
ACCESSION #
44834104

 

Related Articles

  • New FDA Approvals.  // Drug Formulary Review;Oct2007, Vol. 23 Issue 10, p80 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the drug risperidone for treating schizophrenia in adolescents ages 13-17 and for the short-term treatment of bipolar 1 disorder in children and adolescents ages 10-17. According to the article, this marks the...

  • FDA Actions. Elliott, William T. // Infectious Disease Alert;Nov2009 Infectious D, p2 

    The article presents updates on activities by the U.S. Food & Drug Administration (FDA). Schering-Plough received an approval from FDA for its asenapine Saphris for the treatment of schizophrenia and bipolar I disorder in adults. The approved age limit for levocetirizine Xyzal has been lowered...

  • NEWSLINE.  // Monthly Prescribing Reference;May2011, Vol. 27 Issue 5, pA.8 

    The article offers news briefs related to drugs. The Zyclara imiquimod cream from Graceway Pharmaceuticals LLC has been approved as treatment for perianal and genital warts among patients aged 12 years and older. Reports concerning the association of methemoglobinemia with benzocaine products...

  • FDA approves lipidatrophy drug.  // AIDS Alert;Mar2007, Vol. 22 Issue 3, p31 

    The article reports on the decision of the U.S. Food and Drug Administration to approve the lipidatrophy drug Radiesse.

  • FDA approves half-strength Kaletra.  // AIDS Alert;Jan2008, Vol. 23 Issue 1, p10 

    The article reports on the approval given by the U.S. Department of Food and Drug Administration for a new half-strength Kaletra tablet formulation.

  • Tentative FDA approval: Abacavir & lamivudine.  // AIDS Alert;May2009, Vol. 24 Issue 5, p60 

    The article reports that U.S. Food and Drug Administration (FDA) has given tentative approval for abacavir sulfate and lamivudine tablets that will be used in combination with other antiretroviral agents for the treatment of HIV infection.

  • FDA approves fenofibric acid for lipid target controls.  // Hem/Onc Today;3/10/2009, Vol. 10 Issue 5, p58 

    The article reports on the approval of the drug application of a new formulation of fenofibric acid by the U.S. Food and Drug Administration (FDA).

  • FDA Seeks Info On Diabetes Drug.  // San Diego Business Journal;3/22/2010, Vol. 31 Issue 12, p5 

    The article reports on the concerns raised by the U.S. Food and Drug Administration regarding the diabetes drug that was passed by Amylin Pharmaceutical Inc. for approval.

  • ODAC: Pralatrexate recommended for accelerated approval to treat refractory T-cell lymphoma. Harris, Jason // Hem/Onc Today;9/25/2009, Vol. 10 Issue 18, p1 

    The article reports that the Oncologic Drug Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted in favor of the accelerated approval of pralatrexate injection for the treatment of refractory T-cell lymphoma.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics